All In MedTech

Company

AtriCure

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

AtriCure is on our public-company list (ticker ATRC). Naming a company here is not a recommendation of it or of any security.

Financing

Public company. Figures from its SEC financial statements.

Public

Listed

ATRC

Nasdaq · AtriCure, Inc.

Public float

$1.57B

Value of shares held by non-insiders on Jun 30, 2025

Revenue

$535M

Fiscal year ending Dec 31, 2025

Net income

-$11.4M

Fiscal year ending Dec 31, 2025

R&D spending

$99.2M

Fiscal year ending Dec 31, 2025

Cash

$187M

As of Sep 30, 2026

Long-term debt

$61.0M

As of Sep 30, 2026

Shares outstanding

50.9M

As of Nov 2, 2026

Capital raised as a public company

Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.

YearIPOStock soldLong-term debtConvertible debt
2024––$61.2M–
2021––$5.0M–

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

The investor database is part of the paid tier

For AtriCure we have 6 shareholders with 5% or more.

It is included for signed-in readers who have credit. Credit is also what pays for AI device summaries.

Latest FDA decisions

The 8 newest of 35 since 2015.

Search the Clearance Tracker

34 more FDA decisions with a free account

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar
  • NCT05393180 · 53 participants · Start Apr 13, 2022 · Primary completion Feb 26, 2027

    Device: Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF · For: Chronic Atrial Fibrillation

    Sites: San Francisco, California; Hartford, Connecticut; Clearwater, Florida · 13 sites in all

31 more trials with a free account

Reports received

65

Received Nov 1, 2025 to Nov 20, 2026. Includes 1 of another or unstated type.

Malfunction reports

17

26% of reports

Injury reports

39

60% of reports

Death reports

8

12% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 231400
Jan 241400
Feb 2411200
Mar 240620
Apr 242500
May 242800
Jun 240200
Jul 240400
Aug 242300
Sep 241120
Oct 241510
Nov 242300
Dec 241410
Jan 2511000
Feb 252300
Mar 251200
Apr 250200
May 250600
Jun 252200
Jul 252300
Aug 251000
Sep 250200
Oct 251100
Nov 250320
Dec 252720
Jan 262420
Feb 263800
Mar 263200
Apr 261300
May 261310
Jun 260100
Jul 260200
Aug 263311
Sep 261100
Oct 261200
Nov 260000

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

6 more in this ranking with a free account

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

7 more in this ranking with a free account

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

  • Z-0927-2024 · Started Nov 28, 2023 · Posted by FDA Jan 31, 2024

    Reason given: AtriCure has identified certain lots of tank hose assemblies where a second-tier supplier provided incorrect tank hose assemblies. These tank hose assemblies were provided with an outer sheathing that does not have required pin perforations and the inner tube of the hose is not the correct material.

    Cause as FDA categorized it: Other · Device type: Unit, Cryosurgical, Accessories (GEH)

12 more recall records with a free account

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.